journal article·2008-09

Self‐assembling cyclodextrin based hydrogels for the sustained delivery of hydrophobic drugs

S. Daoud‐Mahammed, J. L. Grossiord, T. Bergua, C. Amiel, P. Couvreur, R. Gref

Publisher page

Abstract

Abstract This study aims to investigate the rheological properties of self‐assembling gels containing cyclodextrins with potential application as injectable matrix for the sustained delivery of poorly soluble drugs. The ability of these gels to entrap two hydrophobic molecules, benzophenone (BZ) and tamoxifen (TM), and to allow their in vitro sustained release was evaluated. In view of their future pharmaceutical use, gels were sterilized by high hydrostatic pressures (HHP) and tested for their biocompatibility. The gels formed instantaneously at room temperature, by mixing the aqueous solutions of two polymers: a β‐cyclodextrin polymer (pβCD) and a hydrophobically modified dextran by grafting alkyl side chains (MD). MD‐pβCD gels presented a viscoelastic behavior under low shear, characterized by constant values of the loss modulus G″ and the storage modulus G′. The most stable gels were obtained for a total polymer concentration Cp of 6.6% and 7.5% (w/w), and a polymer ratio MD/pβCD of 50/50 and 33/67 (w/w). BZ and TM were successfully incorporated into MD‐pβCD gels with loading efficiencies as high as 90%. In vitro, TM and BZ were released gradually from the gel matrix with less than 25% and 75% release, respectively, after 6 days incubation. HHP treatment did not modify the rheological characteristics of MD‐pβCD gels. Moreover, the low toxicity of these gels after intramuscular administration in rabbits makes them promising injectable devices for local delivery of drugs. © 2007 Wiley Periodicals, Inc. J Biomed Mater Res 2008
Source: crossref · Quality: baseline

Research context

OpenAlex topics: Polysaccharides Composition and Applications · Hydrogels: synthesis, properties, applications · Drug Solubulity and Delivery Systems

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

References (51)

Show source-provided references
1. 10.1615/CritRevTherDrugCarrierSyst.v12.i1.1010.1615/CritRevTherDrugCarrierSyst.v12.i1.10 ↗
2. 10.1016/S0169-409X(97)00036-710.1016/S0169-409X(97)00036-7 ↗
3. 10.1007/BF0068904310.1007/BF00689043 ↗
4. 10.1016/S0169-409X(97)00050-110.1016/S0169-409X(97)00050-1 ↗
5. Interstitial taxol delivered from a biodegradable polymer implant against experimental malignant glioma
6. 10.3109/0265204900902184210.3109/02652049009021842 ↗
7. 10.1016/0378-5173(95)04320-910.1016/0378-5173(95)04320-9 ↗
8. The United States Pharmacopeia (USP XXIII NF 18) United States Pharmacopeial Convention;1995.
9. 10.1016/S0168-3659(99)00219-910.1016/S0168-3659(99)00219-9 ↗
10. 10.1016/S0168-3659(02)00060-310.1016/S0168-3659(02)00060-3 ↗
11. 10.1016/S0378-5173(00)00628-110.1016/S0378-5173(00)00628-1 ↗
12. 10.1016/j.ejpb.2004.03.00310.1016/j.ejpb.2004.03.003 ↗
13. 10.1016/j.ejpb.2004.03.01910.1016/j.ejpb.2004.03.019 ↗
14. 10.1021/ma00056a00510.1021/ma00056a005 ↗
15. 10.1016/S0168-3659(99)00143-110.1016/S0168-3659(99)00143-1 ↗
16. 10.1016/0168-3659(96)01333-810.1016/0168-3659(96)01333-8 ↗
17. 10.1023/A:101197950569710.1023/A:1011979505697 ↗
18. 10.1615/CritRevTherDrugCarrierSyst.v19.i1.2010.1615/CritRevTherDrugCarrierSyst.v19.i1.20 ↗
19. 10.1016/0168-3659(94)00097-E10.1016/0168-3659(94)00097-E ↗
20. 10.1016/S0169-409X(01)00242-310.1016/S0169-409X(01)00242-3 ↗
21. 10.1002/jbm.82006060910.1002/jbm.820060609 ↗
22. 10.1023/A:101581562433410.1023/A:1015815624334 ↗
23. 10.1016/S0168-3659(97)01648-910.1016/S0168-3659(97)01648-9 ↗
24. 10.1016/S0378-5173(99)00119-210.1016/S0378-5173(99)00119-2 ↗
25. Reeve LE · 1997 · 231
26. 10.1021/js960097g10.1021/js960097g ↗
27. 10.1016/S0168-3659(99)00061-910.1016/S0168-3659(99)00061-9 ↗
28. 10.1016/S0927-7765(99)00069-710.1016/S0927-7765(99)00069-7 ↗
29. 10.1016/S0168-3659(99)00194-710.1016/S0168-3659(99)00194-7 ↗
30. 10.1002/(SICI)1097-4636(200005)50:2<171::AID-JBM11>3.0.CO;2-F10.1002/(SICI)1097-4636(200005)50:2<171::AID-JBM11>3.0.CO;2-F ↗
31. 10.1016/S0142-9612(00)00116-210.1016/S0142-9612(00)00116-2 ↗
32. 10.1016/S0378-5173(00)00428-210.1016/S0378-5173(00)00428-2 ↗
33. 10.1016/S0378-5173(00)00335-510.1016/S0378-5173(00)00335-5 ↗
34. 10.1016/S1773-2247(04)50005-910.1016/S1773-2247(04)50005-9 ↗
35. 10.1016/j.jconrel.2005.12.02510.1016/j.jconrel.2005.12.025 ↗
36. 10.1016/S0014-3057(96)00123-110.1016/S0014-3057(96)00123-1 ↗
37. 10.1016/0032-3861(88)90370-910.1016/0032-3861(88)90370-9 ↗
38. Amiel C · 2001 · 58
39. 10.1016/S0001-8686(98)00070-010.1016/S0001-8686(98)00070-0 ↗
40. 10.1021/bc049811910.1021/bc0498119 ↗
41. Larson RG · 1999
42. 10.1016/S0021-9673(99)00005-910.1016/S0021-9673(99)00005-9 ↗
43. GerloczyA VikmonM SzejtliJ RedentiE VenturaP. In: Academic K editor; Mutual solubility enhancement by binary multicomponent complexation of clomiphene and tamoxifen 9th International Symposium on Cyclodextrins199831 May/3 June Santiago de Compostela. p277–280.10.1007/978-94-011-4681-4_64 ↗
44. 10.1016/0378-4347(87)80040-310.1016/0378-4347(87)80040-3 ↗
45. FisherW KlokkersK Sendl‐LangA; Pharmaceutical composition comprising Z‐4‐hydroxytamoxifen and cyclodextrin patent PCT Int Appl WO9933451 1999.
46. Design and evaluation of an original o/w/o multiple emulsion containing natural cyclodextrins as the emulsifier
47. 10.1039/p2977000141910.1039/p29770001419 ↗
48. 10.1021/j100326a04010.1021/j100326a040 ↗
49. 10.1016/S0924-2244(98)00030-210.1016/S0924-2244(98)00030-2 ↗
50. 10.1177/10820132950010020310.1177/108201329500100203 ↗
51. 10.1023/A:102326730409610.1023/A:1023267304096 ↗